Novo Nordisk’s Three-Way Catalyst: Formulary Reset, EU Pill Approval, and Pipeline Data

Novo Nordisk's Wegovy retains preferred CVS status but will share with Lilly's Zepbound from Oct 2026. European regulators recommend oral Wegovy approval. Stock up 13% monthly but down 36% YoY; ADA data pivotal.

Novo Nordisk enters June with a delicate balancing act. Its blockbuster weight-loss drug Wegovy retains preferred status at a major US pharmacy benefit manager, but that edge is now shared with Eli Lilly’s Zepbound, which returns to the formulary in October. Across the Atlantic, European regulators have just recommended oral Wegovy for approval, handing Novo a head start in the oral GLP-1 race. And starting June 5, the Danish pharma giant will present high-stakes pipeline data at the American Diabetes Association (ADA) meeting in New Orleans. The stock, which has lost more than a third of its value over the past year, is now testing whether these three developments can reverse its fortunes.

CVS Caremark, one of the largest US pharmacy benefit managers, had removed Eli Lilly’s Zepbound from its formularies in May 2025, giving Wegovy exclusive preferred status. That dynamic shifts on October 1, 2026, when Zepbound returns as an additional preferred option. Wegovy — both the injectable and the new oral formulation — stays on the preferred list. The competitive pressure will intensify even earlier, on June 1, 2026, when CVS lifts market-access restrictions on Foundayo, Lilly’s oral GLP-1 therapy. In Europe, however, Lilly’s oral competitor is not expected before 2027, giving Novo a cushion in that region.

European regulators delivered a clear vote of confidence on May 22, 2026. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended marketing authorisation for the Wegovy pill — a once-daily, 25 mg oral semaglutide. If approved, it would become the first oral GLP-1 therapy for weight loss in the EU. The CHMP also backed a higher-dose injectable version of Wegovy, 7.2 mg administered once weekly, supported by data from the STEP-UP trial in which participants achieved an average 20.7% weight loss. Roughly a third lost 25% or more. Novo Nordisk plans to launch the injectable in the EU in the third quarter of 2026, while the oral pill’s launch timeline will follow regulatory approval.

The stock has shown signs of life after a brutal slide. It closed the week at €39.05, up 13% from a month earlier but still down 36% year-on-year and roughly 45% below its 52-week high of €70.13. Shares have recovered 27% from their March low, yet trade below both the 100-day and 200-day moving averages, with a relative strength index near 48 — a neutral reading that leaves room for a move in either direction.

The ADA conference, running from June 5 to 8, is the next major test. Novo Nordisk will present a broad pipeline package, headlined by Phase 3 results from the REIMAGINE program for CagriSema, a fixed-dose combination of the amylin analogue cagrilintide and semaglutide. Data will be discussed in a symposium on June 7, focussing on glycaemic control and body weight in type 2 diabetes patients on various background therapies. Alongside that, Phase 2b results for zenagamtide (formerly known as Amycretin) will be disclosed. This molecule combines GLP-1 and amylin receptor agonism in a single entity and is being developed in both oral and subcutaneous formulations. Neither candidate is yet approved in the US.

In total, Novo Nordisk will showcase 40 abstracts covering indications well beyond obesity, including cardiovascular, renal, and pulmonary conditions such as asthma, sleep apnoea, and MASH. Data on semaglutide, insulin icodec, and the once-weekly IcoSema will also be featured. An R&D investor day has been scheduled for June 7, giving management a dedicated platform to contextualise the results. The breadth of the pipeline is critical: in the first quarter of 2026, adjusted US revenues fell 11% on a constant-currency basis, underscoring the need to demonstrate that the GLP-1 franchise extends far beyond weight reduction.

A structural tailwind may be on the horizon. Starting July 1, 2026, Medicare Part D is expected to reimburse obesity medications for a large portion of beneficiaries. That would significantly expand the addressable market for Wegovy, regardless of how formulary dynamics evolve in the coming months. Analyst Citi recently raised its price target on the stock to 290 Danish kroner, while maintaining a neutral rating.

The convergence of formulary adjustments, European regulatory progress, and a dense pipeline data slate means the next two weeks will be pivotal for Novo Nordisk. The question is whether the clinical conviction from CagriSema, zenagamtide, and the broader portfolio can outweigh the competitive noise and pricing headwinds that have weighed on the shares.